Published in Virology on December 20, 2002
Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol (2005) 1.81
HIV-1 associated dementia: symptoms and causes. Retrovirology (2006) 1.70
HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology (2011) 1.17
The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med (2008) 1.14
Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases. J Virol (2005) 1.02
Oxygen matters: tissue culture oxygen levels affect mitochondrial function and structure as well as responses to HIV viroproteins. Cell Death Dis (2011) 1.00
Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration. Am J Physiol Heart Circ Physiol (2008) 0.97
Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis. Adv Virus Res (2011) 0.94
HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc Natl Acad Sci U S A (2004) 0.93
Modeling gene-by-environment interaction in comorbid depression with alcohol use disorders via an integrated bioinformatics approach. BioData Min (2008) 0.92
Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol (2012) 0.91
Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol (2009) 0.87
Ethanol concentration-dependent alterations in gene expression during acute binge drinking in the HIV-1 transgenic rat. Alcohol Clin Exp Res (2013) 0.86
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. Virol J (2009) 0.85
Age- and ethanol concentration-dependent effects of acute binge drinking in the HIV-1 transgenic rat. Alcohol Clin Exp Res (2012) 0.84
Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes. J Virol (2005) 0.84
Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro. J Virol (2006) 0.84
Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances. Neurobehav HIV Med (2012) 0.80
Methamphetamine effects on blood-brain barrier structure and function. Front Neurosci (2015) 0.78
Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease. Front Microbiol (2016) 0.76
Role of Autophagy in HIV Pathogenesis and Drug Abuse. Mol Neurobiol (2016) 0.75
Platelets Contribute to BBB Disruption Induced by HIV and Alcohol. J Alcohol Drug Depend (2015) 0.75
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest (2005) 2.41
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis (2002) 1.91
Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med (2003) 1.75
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol (2004) 1.69
A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology (2004) 1.54
Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol (2003) 1.53
Central nervous system infections in individuals with HIV-1 infection. J Neurovirol (2002) 1.48
Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med (2008) 1.45
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology (2002) 1.33
Antiviral potentials of medicinal plants. Virus Res (2007) 1.22
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J Virol (2003) 1.19
HIV-1 transmission and cytokine-induced expression of DC-SIGN in human monocyte-derived macrophages. J Leukoc Biol (2003) 1.18
Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem (2002) 1.17
Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses (2004) 1.10
The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. Virology (2005) 1.08
The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology (2007) 1.08
RNA interference: on the road to an alternate therapeutic strategy! Rev Med Virol (2003) 1.06
Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem (2008) 1.05
Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses (2003) 1.04
siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology (2006) 1.03
Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases. J Virol (2005) 1.02
Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res (2003) 1.02
Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol (2002) 1.01
Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology (2006) 0.98
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis (2007) 0.98
IL-7 as a potential therapy for HIV-1-infected individuals. Expert Opin Biol Ther (2005) 0.98
Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J Virol (2004) 0.98
Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. Virology (2002) 0.97
Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ. Virology (2003) 0.96
Prevalence of Helicobacter pylori pathogenicity-associated cagA and vacA genotypes among Pakistani dyspeptic patients. FEMS Immunol Med Microbiol (2008) 0.96
Rev binds specifically to a purine loop in the SL1 region of the HIV-1 leader RNA. J Biol Chem (2003) 0.95
Lentiviral expression of HIV-1 Vpr induces apoptosis in human neurons. J Neurovirol (2002) 0.94
Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS (2002) 0.94
HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc Natl Acad Sci U S A (2004) 0.93
Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J Virol (2004) 0.93
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr (2004) 0.93
Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol (2003) 0.91
Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology (2005) 0.90
HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses (2005) 0.89
HIV-1 Vpr potently induces programmed cell death in the CNS in vivo. DNA Cell Biol (2007) 0.88
Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Clin Infect Dis (2002) 0.88
Antiretroviral therapy in the developing world. J Neurovirol (2005) 0.88
Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells. J Virol (2005) 0.87
Malaria vectors in the changing environment of the southern Punjab, Pakistan. Trans R Soc Trop Med Hyg (2004) 0.87
RNA interference meets HIV-1: will silence be golden? Nat Med (2002) 0.86
Attenuation of HIV-1 infection by other microbial agents. J Infect Dis (2005) 0.86
Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry (2003) 0.86
Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo. Virology (2003) 0.86
Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging. J Gen Virol (2006) 0.86
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. Virol J (2009) 0.85
The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. Virology (2003) 0.84
Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro. J Virol (2006) 0.84
Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes. J Virol (2005) 0.84
HIV: cross-talk and viral reservoirs. Nature (2003) 0.84
Combined abdominal hysterectomy, cholecystectomy and appendicectomy: a study of 25 cases in Abbottabad. J Ayub Med Coll Abbottabad (2006) 0.83
Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. AIDS Patient Care STDS (2003) 0.83
A two years audit of complications of hysterectomy at Ayub Teaching Hospital Abbottabad. J Ayub Med Coll Abbottabad (2005) 0.82
Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. J Neurovirol (2005) 0.82
Combination genetic therapy to inhibit HIV-1. Mol Ther (2002) 0.82
ATM: HIV-1's Achilles heel? Nat Cell Biol (2005) 0.81
Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways. Virology (2005) 0.81
Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions. PLoS One (2013) 0.81
The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity. Virology (2004) 0.81
A trans-dominant negative HIV type 1 Rev with intact domains of NLS/NOS and NES. AIDS Res Hum Retroviruses (2002) 0.80
Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses (2005) 0.80
Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. Virology (2003) 0.80
Determination of pesticide residues in rice grain by solvent extraction, column cleanup, and gas chromatography-electron capture detection. Bull Environ Contam Toxicol (2010) 0.80
Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines. Chem Commun (Camb) (2010) 0.79
Clinical audit of foetomaternal outcome in pregnancies with fibroid uterus. J Ayub Med Coll Abbottabad (2013) 0.79
Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology (2003) 0.79